We’ve recently updated our valuation analysis.

Pacific Edge Valuation

Is PEB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PEB?

Other financial metrics that can be useful for relative valuation.

PEB key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue19x
Enterprise Value/EBITDA-12.5x
PEG Ration/a

Price to Sales Ratio vs Peers

How does PEB's PS Ratio compare to its peers?

The above table shows the PS ratio for PEB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average5.9x
AFT AFT Pharmaceuticals
2.8x14.3%NZ$398.5m
XOMA XOMA
5.7x16.2%US$232.3m
GRTS Gritstone bio
14.1x28.8%US$265.1m
ALERS Eurobio Scientific Société anonyme
1.1x-11.0%€192.0m
PEB Pacific Edge
25.1x48.0%NZ$405.2m

Price-To-Sales vs Peers: PEB is expensive based on its Price-To-Sales Ratio (25.1x) compared to the peer average (5.9x).


Price to Earnings Ratio vs Industry

How does PEB's PE Ratio compare vs other companies in the Oceanian Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.1%
n/an/an/a

Price-To-Sales vs Industry: PEB is expensive based on its Price-To-Sales Ratio (25.1x) compared to the Oceanic Biotechs industry average (18.8x)


Price to Sales Ratio vs Fair Ratio

What is PEB's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PEB PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio25.1x
Fair PS Ratio15x

Price-To-Sales vs Fair Ratio: PEB is expensive based on its Price-To-Sales Ratio (25.1x) compared to the estimated Fair Price-To-Sales Ratio (15x).


Share Price vs Fair Value

What is the Fair Price of PEB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PEB's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PEB's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PEB forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentNZ$0.51
NZ$0.59
+16.3%
19.3%NZ$0.75NZ$0.48n/a3
Jan ’24NZ$0.50
NZ$0.59
+19.0%
19.1%NZ$0.75NZ$0.48n/a3
Dec ’23NZ$0.45
NZ$0.59
+33.7%
19.1%NZ$0.75NZ$0.48n/a3
Nov ’23NZ$0.42
NZ$0.72
+70.9%
8.4%NZ$0.77NZ$0.63n/a3
Oct ’23NZ$0.50
NZ$0.72
+43.5%
8.4%NZ$0.77NZ$0.63n/a3
Sep ’23NZ$0.46
NZ$0.72
+57.7%
8.4%NZ$0.77NZ$0.63n/a3
Aug ’23NZ$0.48
NZ$0.86
+76.6%
16.0%NZ$1.05NZ$0.75n/a3
Jul ’23NZ$0.68
NZ$0.91
+33.3%
12.6%NZ$1.05NZ$0.77n/a3
Jun ’23NZ$0.83
NZ$0.97
+16.9%
6.4%NZ$1.05NZ$0.90n/a3
May ’23NZ$0.90
NZ$1.14
+26.3%
14.2%NZ$1.35NZ$0.96n/a3
Apr ’23NZ$0.99
NZ$1.24
+24.9%
15.9%NZ$1.40NZ$0.96n/a3
Mar ’23NZ$0.96
NZ$1.50
+56.3%
6.7%NZ$1.60NZ$1.40n/a2
Feb ’23NZ$1.09
NZ$1.50
+37.6%
6.7%NZ$1.60NZ$1.40NZ$0.512
Jan ’23NZ$1.33
NZ$1.50
+12.8%
6.7%NZ$1.60NZ$1.40NZ$0.502
Dec ’22NZ$1.26
NZ$1.50
+19.0%
6.7%NZ$1.60NZ$1.40NZ$0.452
Nov ’22NZ$1.45
NZ$1.50
+3.4%
6.7%NZ$1.60NZ$1.40NZ$0.422
Oct ’22NZ$1.50
NZ$1.60
+6.7%
0%NZ$1.60NZ$1.60NZ$0.501
Sep ’22NZ$1.39
NZ$1.50
+7.9%
6.7%NZ$1.60NZ$1.40NZ$0.462
Aug ’22NZ$1.24
NZ$1.50
+21.0%
6.7%NZ$1.60NZ$1.40NZ$0.482
Jul ’22NZ$1.23
NZ$1.50
+22.0%
6.7%NZ$1.60NZ$1.40NZ$0.682
Jun ’22NZ$1.20
NZ$1.50
+25.0%
6.7%NZ$1.60NZ$1.40NZ$0.832
May ’22NZ$1.15
NZ$1.50
+30.4%
6.7%NZ$1.60NZ$1.40NZ$0.902
Apr ’22NZ$1.01
NZ$1.50
+48.5%
6.7%NZ$1.60NZ$1.40NZ$0.992
Mar ’22NZ$1.04
NZ$1.50
+44.2%
6.7%NZ$1.60NZ$1.40NZ$0.962
Feb ’22NZ$1.05
NZ$1.50
+42.9%
6.7%NZ$1.60NZ$1.40NZ$1.092

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies